Clinical Trial Update: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy [Phase 2]

View source ↗

Summary

A Phase II trial evaluating ertumaxomab for metastatic breast cancer after progression on trastuzumab was terminated. Results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ertumaxomab (ertumaxomab)

Snippet

Sponsor: Neovii Biotech | Conditions: Metastatic Breast Cancer, Advanced Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2011-04-29